Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| Name | of entity | Bioxyne Limited | | |
|------|------------|-----------------|--|--|
| ABN | 97 084 464 | 193 | | |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Mr Jason Hine |
|---------------------|------------------|
| Date of last notice | 19 December 2024 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct and Indirect | |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Hine Lamont Pty Ltd As trustee for The "Hine Lamont Family Trust" | |
| Date of change | 27 October 2025 | |
| No. of securities held prior to change | 1,324,890 ordinary shares 14,500,000 performance rights | |
| Class | Performance Rights | |
| Number acquired | 4,500,000 | |
| Number disposed | Nil | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil | |
| No. of securities held after change | 1,324,890 ordinary shares held directly 4,500,000 ordinary shares held indirectly 10,000,000 performance rights | |

⁺ See chapter 19 for defined terms.

11/3/2002 Appendix 3Y Page 1

| Example: on-market trade, off-market trade, exercise of options, issue of | Award of shares on performance milestones for 2023 to 2025 having been met. |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| securities under dividend reinvestment plan, participation in buy-back | for 2023 to 2023 having seen met. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | N/A |
|--------------------------------------------------------------------------|-----|
| Nature of interest | |
| Name of registered holder | |
| | |
| (if issued securities) | |
| Date of change | |
| | |
| No. and class of securities to | |
| which interest related prior to | |
| | |
| change Note: Details are only required for a contract in relation | |
| to which the interest has changed | |
| | |
| Interest acquired | |
| • | |
| | |
| Interest disposed | |
| | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and an | |
| estimated valuation | |
| Interest after change | |
| 5 | |
| | |

Part 3 – +Closed period

| Were the interests in the securities or contracts detailed | No |
|------------------------------------------------------------|-----|
| above traded during a +closed period where prior | |
| written clearance was required? | |
| If so, was prior written clearance provided to allow the | N/A |
| trade to proceed during this period? | |
| If prior written clearance was provided, on what date | N/A |
| was this provided? | |

Appendix 3Y Page 2 11/3/2002

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

| Name of entity | Bioxyne Limited | |
|----------------|-----------------|--|
| ABN 97 084 464 | 4 193 | |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Mr Samuel Watson |
|---------------------|------------------|
| Date of last notice | 19 December 2024 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct & Indirect | |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Breathe International Limited in which company Mr Samuel Watson holds a controlling interest | |
| | Zonetech Wellness Limited, a subsidiary company of Breathe International Limited | |
| Date of change | 27 October 2025 | |
| No. of securities held prior to change | Breathe International Limited 576,268,527 Zonetech Wellness Limited 57,732,857 Samuel Watson 999,362 shares Performance rights 33,500,000 | |
| Class | Ordinary shares on vesting of performance rights | |
| Number acquired | 13,500,000 | |
| Number disposed | Nil | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil | |

⁺ See chapter 19 for defined terms.

11/3/2002 Appendix 3Y Page 1

| No. of securities held after change | Breathe International Limited 576,268,527 Zonetech Wellness Limited 57,732,857 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| | Samuel Watson 14,499,362 shares Performance rights 20,000,000 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Award of shares on milestones for 2023 to 2025 performance rights being achieved. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | N/A |
|----------------------------------------------------------------------------------------------|-----|
| | |
| Nature of interest | |
| | |
| Name of registered holder | |
| (if issued securities) | |
| | |
| Date of change | |
| | |
| No. and class of securities to | |
| which interest related prior to | |
| change | |
| Note: Details are only required for a contract in relation to which the interest has changed | |
| to which the interest has changed | |
| Interest acquired | |
| | |
| Interest disposed | |
| was p | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and an | |
| estimated valuation | |
| Interest after change | |
| Interest after change | |
| | |

Part 3 – +Closed period

| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---------------------------------------------------------------------------------------------------------------------------------------------|-----|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

Appendix 3Y Page 2 11/3/2002

⁺ See chapter 19 for defined terms.